Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML - Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G., Goldberg, S. L., Perl, A. E., Marie, J.-P., Martinelli, G., Kantarjian, H. M., Levis, M. J. (American Society of Hematology (ASH), 2018)
6317264